CN108472303A - 用于治疗白内障的组合物 - Google Patents

用于治疗白内障的组合物 Download PDF

Info

Publication number
CN108472303A
CN108472303A CN201680055951.6A CN201680055951A CN108472303A CN 108472303 A CN108472303 A CN 108472303A CN 201680055951 A CN201680055951 A CN 201680055951A CN 108472303 A CN108472303 A CN 108472303A
Authority
CN
China
Prior art keywords
composition
cholestene
alcohol
steroids
cholesteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680055951.6A
Other languages
English (en)
Chinese (zh)
Inventor
萨姆·L·恩固因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concores Co
Original Assignee
Concores Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concores Co filed Critical Concores Co
Publication of CN108472303A publication Critical patent/CN108472303A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680055951.6A 2015-07-27 2016-07-27 用于治疗白内障的组合物 Pending CN108472303A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562197477P 2015-07-27 2015-07-27
US62/197,477 2015-07-27
US201562202518P 2015-08-07 2015-08-07
US62/202,518 2015-08-07
US201562252120P 2015-11-06 2015-11-06
US62/252,120 2015-11-06
US201662295267P 2016-02-15 2016-02-15
US62/295,267 2016-02-15
PCT/US2016/044337 WO2017019808A1 (en) 2015-07-27 2016-07-27 Compositions for the treatment of cataracts

Publications (1)

Publication Number Publication Date
CN108472303A true CN108472303A (zh) 2018-08-31

Family

ID=56616065

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680055951.6A Pending CN108472303A (zh) 2015-07-27 2016-07-27 用于治疗白内障的组合物

Country Status (7)

Country Link
US (2) US10398709B2 (enExample)
EP (1) EP3328389A1 (enExample)
JP (1) JP2018522070A (enExample)
CN (1) CN108472303A (enExample)
AU (1) AU2016298951B2 (enExample)
CA (1) CA2993196A1 (enExample)
WO (1) WO2017019808A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023020536A1 (zh) * 2021-08-18 2023-02-23 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2023020535A1 (zh) * 2021-08-18 2023-02-23 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗飞蚊症的药物中的应用
WO2023030430A1 (zh) 2021-09-03 2023-03-09 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN118354765A (zh) * 2021-08-06 2024-07-16 福德维卡股份制公司 用于治疗视觉障碍的眼用组合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
EP3086793B1 (en) 2013-12-24 2022-05-11 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
CN108350021A (zh) * 2015-09-08 2018-07-31 视点医疗公司 用于治疗眼科疾病的化合物和制剂
KR102593667B1 (ko) 2016-08-02 2023-10-24 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
CA3078680A1 (en) * 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
WO2020003051A1 (en) * 2018-06-27 2020-01-02 Cellix Bio Private Limited Ophthalmic compositions and methods for the treatment of eye disorders
JP2022529363A (ja) * 2019-04-19 2022-06-21 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ｃｒｙａｂ凝集阻害剤である２５－ヒドロキシコレステロール（２５ｈｃ）は新規の老化細胞除去剤である
EP4467144A4 (en) 2022-01-21 2026-01-21 Senju Usa Inc AQUEOUS LIQUID FORMULATION
AU2023411014A1 (en) * 2022-12-23 2025-08-07 Durect Corporation 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4192827A (en) 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4136250A (en) 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US20020132758A1 (en) 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
CN104768615B (zh) * 2012-07-17 2019-02-22 密执安大学评议会 治疗白内障的非手术方法
EP2890363A1 (en) 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
WO2015085121A1 (en) * 2013-12-05 2015-06-11 University Of Miami Compositions and methods for reducing intraocular pressure
WO2016029197A1 (en) 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye
CA2958868A1 (en) * 2014-08-22 2016-02-25 Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. Compositions and methods to treat vision disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No relevant documents disclosed *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118354765A (zh) * 2021-08-06 2024-07-16 福德维卡股份制公司 用于治疗视觉障碍的眼用组合物
WO2023020536A1 (zh) * 2021-08-18 2023-02-23 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2023020535A1 (zh) * 2021-08-18 2023-02-23 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗飞蚊症的药物中的应用
CN117693346A (zh) * 2021-08-18 2024-03-12 广州润尔眼科生物科技有限公司 甾体化合物在制备预防和/或治疗飞蚊症的药物中的应用
CN117693346B (zh) * 2021-08-18 2026-02-10 润尔眼科药物（广州）有限公司 甾体化合物在制备预防和/或治疗飞蚊症的药物中的应用
WO2023030430A1 (zh) 2021-09-03 2023-03-09 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂

Also Published As

Publication number Publication date
EP3328389A1 (en) 2018-06-06
AU2016298951B2 (en) 2019-07-04
AU2016298951A1 (en) 2018-02-22
WO2017019808A1 (en) 2017-02-02
US20200016176A1 (en) 2020-01-16
CA2993196A1 (en) 2017-02-02
JP2018522070A (ja) 2018-08-09
US10398709B2 (en) 2019-09-03
US20170027961A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
CN108472303A (zh) 用于治疗白内障的组合物
USRE50218E1 (en) Non-steroidal anti-inflammatory ophthalmic compositions
EP3034072B1 (en) Controlled-release ophthalmic vehicles
WO2013096857A1 (en) Combination anti-inflammatory ophthalmic compositions
US9289396B2 (en) Collagen-based implants for sustained delivery of drugs
US20070287749A1 (en) Bromfenac ophthalmic formulations and methods of use
US20130217657A1 (en) Combination anti-inflammatory ophthalmic compositions
TW200800267A (en) Pharmaceutical formulations comprising polyanionic materials and Zinc-based preservatives
TW201642914A (zh) 用於治療眼部疾病及失調的裝置及方法
ES2984281T3 (es) Composiciones que comprenden un antagonista de la aldosterona para su uso en el tratamiento de ojos secos
US20240252446A1 (en) Derivatized collagen-hyaluronic acid based implants for sustained delivery of ophthalmic drugs
WO2014160579A1 (en) Combination anti-inflammatory ophthalmic compositions
TW201350124A (zh) 用於治療、控制、改善或逆轉乾眼症之病狀之醫藥組合物及方法
WO2025221795A1 (en) Growth and differentiation factor 15 for treatment of posterior capsular opacification

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180831